The NAMPT inhibitor, FK866, was evaluated in various nude mouse xenograft models (e.g., ovarian cancer, pancreatic cancer, and colon cancer), and showed strong efficacy in phase I and II clinical trials for advanced or metastatic solid tumors, refractory lymphoma, and advanced pancreatic cancer [30,36,41]. This evidence concerns the gene NAMPT and pancreatic neoplasm.